Using MRD Status a Endpoint for Drug Approval image

Using MRD Status a Endpoint for Drug Approval

Feb 24, 2022
07:00PM - 08:00PM EST
Online Event
Overview

While more myeloma specialists are accepting the importance of testing for minimal residual disease (MRD), it's harder to agree on what to do with those test results. One of the questions yet to answer is whether or not MRD results should be used as an endpoint on clinical trials.

Listen to Dr. Manni Mohyuddin as he shares his opinion on the subject. This kind of myeloma research can get us quicker to a cure!

Agenda
07:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Manni Mohyuddin.
07:05 PM
Presentation
Dr. Manni Mohyuddin, MD
Dr. Manni Mohyuddin shares his opinion minimal residual disease (MRD) testing and what to do with the results. 
07:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Ghulam (Manni) Mohyuddin, MD

Ghulam (Manni) Mohyuddin, MD

Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. After residency, he pursued Chief Residency at the University of Kansas, focusing on mechanisms of novel educational delivery and improving access to research for trainees. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma.